The U.S. Food and Drug Administration said On Tuesday that the Novel Coronavirus (COVID-19) vaccine developed by Moderna contained “no special safety concerns” and that the data met the requirements for emergency use.
According to foreign media reports, the FDA today issued a brief document before an outside expert meeting to discuss whether to approve the Modena vaccine for emergency use, confirming that the overall protection of the vaccine is 94.1% and that “no specific safety concerns have been identified that could prevent the issuance of EUA” (emergency use authorization).
Two doses of the Modena vaccine must be administered 28 days apart. The first dose appeared to reduce the risk of contracting Wuhan pneumonia by about 63 percent, but only two doses had the full protective effect, according to FDA documents.
The Modena vaccine is expected to be approved by the FDA as early as 18 days, according to US media.
Recent Comments